New England Journal of Medicine

No abstract text is available yet for this article.

BACKGROUND: Severe tricuspid regurgitation is a debilitating condition that is associated with substantial morbidity and often with poor quality of life. Decreasing tricuspid regurgitation may reduce symptoms and improve clinical outcomes in patients with this disease. METHODS: We conducted a prospective randomized trial of percutaneous tricuspid transcatheter edge-to-edge repair (TEER) for severe tricuspid regurgitation. Patients with symptomatic severe tricuspid regurgitation were enrolled at 65 centers in the United States, Canada, and Europe and were randomly assigned in a 1:1 ratio to receive either TEER or medical therapy (control)...

No abstract text is available yet for this article.

New England Journal of Medicine, Volume 388, Issue 10, Page 865-867, March 2023.

BACKGROUND: Bempedoic acid, an ATP citrate lyase inhibitor, reduces low-density lipoprotein (LDL) cholesterol levels and is associated with a low incidence of muscle-related adverse events; its effects on cardiovascular outcomes remain uncertain. METHODS: We conducted a double-blind, randomized, placebo-controlled trial involving patients who were unable or unwilling to take statins owing to unacceptable adverse effects ("statin-intolerant" patients) and had, or were at high risk for, cardiovascular disease...

New England Journal of Medicine, Volume 388, Issue 10, Page 870-871, March 2023.

New England Journal of Medicine, Volume 388, Issue 12, Page 1137-1138, March 2023.

BACKGROUND: The benefits and risks of augmenting or switching antidepressants in older adults with treatment-resistant depression have not been extensively studied. METHODS: We conducted a two-step, open-label trial involving adults 60 years of age or older with treatment-resistant depression. In step 1, patients were randomly assigned in a 1:1:1 ratio to augmentation of existing antidepressant medication with aripiprazole, augmentation with bupropion, or a switch from existing antidepressant medication to bupropion...

No abstract text is available yet for this article.

New England Journal of Medicine, Volume 388, Issue 12, Page 1151-1152, March 2023.

No abstract text is available yet for this article.

New England Journal of Medicine, Volume 388, Issue 12, Page 1142-1145, March 2023.

New England Journal of Medicine, Volume 388, Issue 9, Page 774-776, March 2023.

New England Journal of Medicine, Volume 388, Issue 9, March 2023.

New England Journal of Medicine, Volume 388, Issue 9, Page 771-773, March 2023.

New England Journal of Medicine, Volume 388, Issue 9, Page 769-771, March 2023.

No abstract text is available yet for this article.

New England Journal of Medicine, Volume 388, Issue 10, March 2023.

New England Journal of Medicine, Volume 388, Issue 12, Page 1061-1063, March 2023.

BACKGROUND: Tuberculosis is usually treated with a 6-month rifampin-based regimen. Whether a strategy involving shorter initial treatment may lead to similar outcomes is unclear. METHODS: In this adaptive, open-label, noninferiority trial, we randomly assigned participants with rifampin-susceptible pulmonary tuberculosis to undergo either standard treatment (rifampin and isoniazid for 24 weeks with pyrazinamide and ethambutol for the first 8 weeks) or a strategy involving initial treatment with an 8-week regimen, extended treatment for persistent clinical disease, monitoring after treatment, and retreatment for relapse...